110 related articles for article (PubMed ID: 11425383)
1. Raised endothelial microparticles an early marker for multiple sclerosis?
Larkin M
Lancet; 2001 May; 357(9269):1679. PubMed ID: 11425383
[No Abstract] [Full Text] [Related]
2. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
3. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
4. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.
Alexander JS; Chervenak R; Weinstock-Guttman B; Tsunoda I; Ramanathan M; Martinez N; Omura S; Sato F; Chaitanya GV; Minagar A; McGee J; Jennings MH; Monceaux C; Becker F; Cvek U; Trutschl M; Zivadinov R
J Neurol Sci; 2015 Aug; 355(1-2):84-9. PubMed ID: 26073484
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic and prognostic potential of MRI in multiple sclerosis].
Pronin IN; Beliaeva IA; Boĭko AN; Kornienko VN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):18-24. PubMed ID: 12938630
[No Abstract] [Full Text] [Related]
6. MRI lesion loads and disability relationships in MS: more similar than different?
Wolinsky JS
Neurology; 2009 Nov; 73(19):1524-5. PubMed ID: 19828867
[No Abstract] [Full Text] [Related]
7. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
Yun JW; Cvek U; Kilgore PCSR; Tsunoda I; Omura S; Sato F; Zivadinov R; Ramanathan M; Minagar A; Alexander JS
Life Sci; 2019 Jul; 229():116-123. PubMed ID: 31082401
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
9. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
Lebrun C
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
[TBL] [Abstract][Full Text] [Related]
10. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MR imaging of multiple sclerosis: added clinical value or "just another pretty face?".
Lev MH
AJNR Am J Neuroradiol; 2000 May; 21(5):805-8. PubMed ID: 10815651
[No Abstract] [Full Text] [Related]
14. Primary progressive multiple sclerosis: progress and challenges.
Rice CM; Cottrell D; Wilkins A; Scolding NJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1100-6. PubMed ID: 23418213
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
16. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
DeMarshall C; Goldwaser EL; Sarkar A; Godsey GA; Acharya NK; Thayasivam U; Belinka BA; Nagele RG
J Neuroimmunol; 2017 Aug; 309():51-57. PubMed ID: 28601288
[TBL] [Abstract][Full Text] [Related]
18. Making the diagnosis of multiple sclerosis.
Palace J
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii3-8. PubMed ID: 11701777
[No Abstract] [Full Text] [Related]
19. [The role of MRI in the diagnosis and the natural course of multiple sclerosis].
Tourbah A; Lyon-Caen O
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):757-60. PubMed ID: 11677395
[TBL] [Abstract][Full Text] [Related]
20. Sunshine and multiple sclerosis.
Taylor BV
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1066. PubMed ID: 23463872
[No Abstract] [Full Text] [Related]
[Next] [New Search]
